TRVI

Trevi Therapeutics, Inc. TRVI

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-17.80M

Quarter to Jun 30

Free cash flow

$-17.55M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$2.76B total
NEA Management Company, LLC
$246.59M0.0%
FMR LLC
$234.30M+56.3%
BlackRock, Inc.
$208.04M+8.9%
Frazier Life Sciences Management, L.P.
$185.37M0.0%
WELLINGTON MANAGEMENT GROUP LLP
$106.02M+9.5%
VANGUARD CAPITAL MANAGEMENT LLC
$103.15M+11.1%
Vivo Capital, LLC
$95.02M0.0%
Woodline Partners LP
$76.12M+307.8%
Vestal Point Capital, LP
$57.81M+43.1%
MPM BioImpact LLC
$57.32M-6.8%
FRONTIER CAPITAL MANAGEMENT CO LLC
$57.27M+54.0%
STATE STREET CORP
$56.46M+13.6%
GEODE CAPITAL MANAGEMENT, LLC
$54.62M+5.4%
MARSHALL WACE, LLP
$49.87M-32.6%
EVENTIDE ASSET MANAGEMENT, LLC
$49.61M+1.4%
Rubric Capital Management LP
$46.71M-32.5%
Artia Global Partners LP
$41.23M+9.8%
ACORN CAPITAL ADVISORS, LLC
$40.00M0.0%
First Light Asset Management, LLC
$39.11MNew
Pictet Asset Management Holding SA
$37.56M+18.0%
Logos Global Management LP
$35.06M-21.7%
Affinity Asset Advisors, LLC
$33.57M-10.0%
EMERALD ADVISERS, LLC
$33.53M-2.3%
Siren, L.L.C.
$33.33M0.0%
Pivotal bioVenture Partners Investment Advisor LLC
$32.50M+12.2%
See all 220 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/TRVI

Earnings Per Share

13fpro.ai/company/TRVI

Loading ratio trend…

TRVI insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Trevi Therapeutics, Inc. (TRVI): stock profile, AI score and financials

Trevi Therapeutics, Inc. (TRVI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. TRVI is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Trevi Therapeutics, Inc. reports net income of $-17.8M, free cash flow of $-17.6M. Top institutional holders of TRVI by reported 13-F value include NEA Management Company, FMR, BlackRock, based on the most recent SEC filings. TRVI trades on the Nasdaq exchange and files with the SEC under CIK 1563880. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TRVI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Trevi Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1563880 →